Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05576467 · ClinicalTrials.gov registry record · NA
Treatment for Migraine and Mood
A NA study of Migraine and Depressive Symptoms, sponsored by Amanda Shallcross.
- Active
- Registry status
- NA
- Development phase
- 145
- Enrollment target
- 3
- Study locations
NCT05576467: Active NA study of Migraine and Depressive Symptoms, sponsored by Amanda Shallcross.
NCT05576467 is a NA study of Migraine and Depressive Symptoms that is active but no longer recruiting, run by Amanda Shallcross. The registered enrollment target is 145 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (59% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05576467, a NA study of Migraine and Depressive Symptoms, is active but no longer recruiting, sponsored by Amanda Shallcross.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 145 participants
- Enrollment target
- 3
- Study locations
Study Summary
The researchers propose a three-arm pilot study of Mindfulness-Based Cognitive Therapy (MBCT) delivered via telephone (MBCT-T), video (MBCT-V) or Enhanced Usual Care (EUC).
Primary Outcome
Treatment Session Adherence is a measure of treatment feasibility. This measure will be assessed through electronic monitoring of the attendance logs of each treatment session. The number of treatment sessions attended will be recorded. A treatment arm will be considered feasible if participants attended/read 75% of sessions on average.
Conditions Studied
Interventions
- BEHAVIORAL Enhanced Usual Care (EUC)
- BEHAVIORAL MBCT-Telephone
- BEHAVIORAL MBCT-Video
Study Locations (3)
New York
- Albert Einstein College of Medicine - The Bronx
North Carolina
- Wake Forest University School of Medicine - Winston-Salem
Ohio
- The Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2024-03-17 |
| Est. Completion | 2026-10-20 |
| Phase | NA |
What the registry record for NCT05576467 still lists
NCT05576467 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Migraine appearing as the primary indexed condition, and to 3 interventions - of which Enhanced Usual Care (EUC) is the first listed.
NCT05576467 reports a single indexed study location in New York, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT05576467 about?
NCT05576467 is a clinical study titled "Treatment for Migraine and Mood". The researchers propose a three-arm pilot study of Mindfulness-Based Cognitive Therapy (MBCT) delivered via telephone (MBCT-T), video (MBCT-V) or Enhanced Usual Care (EUC).
What is the current status of trial NCT05576467?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 145 participants. The study started on 2024-03-17. Estimated completion is 2026-10-20.
What conditions does trial NCT05576467 study?
This clinical trial studies the following conditions: Migraine, Depressive Symptoms.
What interventions are being tested in trial NCT05576467?
The interventions under investigation include: Enhanced Usual Care (EUC) (BEHAVIORAL), MBCT-Telephone (BEHAVIORAL), MBCT-Video (BEHAVIORAL).
Who is sponsoring clinical trial NCT05576467?
This trial is sponsored by Amanda Shallcross, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05576467 being conducted?
This trial has 3 study locations across New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05576467's enrollment target sits among peer trials
145 51st of 102 higher than 52 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Cocoa Extract for Migraine Trial
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI